644 related articles for article (PubMed ID: 24996165)
1. Whole-genome sequencing analysis reveals high specificity of CRISPR/Cas9 and TALEN-based genome editing in human iPSCs.
Smith C; Gore A; Yan W; Abalde-Atristain L; Li Z; He C; Wang Y; Brodsky RA; Zhang K; Cheng L; Ye Z
Cell Stem Cell; 2014 Jul; 15(1):12-3. PubMed ID: 24996165
[No Abstract] [Full Text] [Related]
2. Advances in therapeutic CRISPR/Cas9 genome editing.
Savić N; Schwank G
Transl Res; 2016 Feb; 168():15-21. PubMed ID: 26470680
[TBL] [Abstract][Full Text] [Related]
3. Rapid Control of Genome Editing in Human Cells by Chemical-Inducible CRISPR-Cas Systems.
Liu KI; Ramli MNB; Sutrisnoh NB; Tan MH
Methods Mol Biol; 2018; 1772():267-288. PubMed ID: 29754234
[TBL] [Abstract][Full Text] [Related]
4. Plant genome engineering in full bloom.
Lozano-Juste J; Cutler SR
Trends Plant Sci; 2014 May; 19(5):284-7. PubMed ID: 24674878
[TBL] [Abstract][Full Text] [Related]
5. [CRISPR/Cas system for genome editing in pluripotent stem cells].
Vasil'eva EA; Melino D; Barlev NA
Tsitologiia; 2015; 57(1):19-30. PubMed ID: 25872372
[TBL] [Abstract][Full Text] [Related]
6. CRISPR-Cas12a: Functional overview and applications.
Paul B; Montoya G
Biomed J; 2020 Feb; 43(1):8-17. PubMed ID: 32200959
[TBL] [Abstract][Full Text] [Related]
7. Selection and Validation of Spacer Sequences for CRISPR-Cas9 Genome Editing and Transcription Regulation in Bacteria.
Grenier F; Lucier JF; Rodrigue S
Methods Mol Biol; 2015; 1334():233-44. PubMed ID: 26404154
[TBL] [Abstract][Full Text] [Related]
8. Generating a Genome Editing Nuclease for Targeted Mutagenesis in Human Cells.
He Z; Kee K
Methods Mol Biol; 2017; 1498():153-162. PubMed ID: 27709574
[TBL] [Abstract][Full Text] [Related]
9. Genome editing: The domestication of Cas9.
Urnov F
Nature; 2016 Jan; 529(7587):468-9. PubMed ID: 26819037
[No Abstract] [Full Text] [Related]
10. Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing.
Veres A; Gosis BS; Ding Q; Collins R; Ragavendran A; Brand H; Erdin S; Cowan CA; Talkowski ME; Musunuru K
Cell Stem Cell; 2014 Jul; 15(1):27-30. PubMed ID: 24996167
[TBL] [Abstract][Full Text] [Related]
11. CRISPR-Cas9: A revolution in genome editing in rheumatic diseases.
Duroux-Richard I; Giovannangeli C; Apparailly F
Joint Bone Spine; 2017 Jan; 84(1):1-4. PubMed ID: 27825565
[No Abstract] [Full Text] [Related]
12. CRISPR/Cas9-Mediated Gene Knockout and Knockin Human iPSCs.
Petazzi P; Menéndez P; Sevilla A
Methods Mol Biol; 2022; 2454():559-574. PubMed ID: 33190185
[TBL] [Abstract][Full Text] [Related]
13. Development of CRISPR/Cas9 system for targeted DNA modifications and recent improvements in modification efficiency and specificity.
Shin J; Oh JW
BMB Rep; 2020 Jul; 53(7):341-348. PubMed ID: 32580834
[TBL] [Abstract][Full Text] [Related]
14. Targeted gene correction minimally impacts whole-genome mutational load in human-disease-specific induced pluripotent stem cell clones.
Suzuki K; Yu C; Qu J; Li M; Yao X; Yuan T; Goebl A; Tang S; Ren R; Aizawa E; Zhang F; Xu X; Soligalla RD; Chen F; Kim J; Kim NY; Liao HK; Benner C; Esteban CR; Jin Y; Liu GH; Li Y; Izpisua Belmonte JC
Cell Stem Cell; 2014 Jul; 15(1):31-6. PubMed ID: 24996168
[TBL] [Abstract][Full Text] [Related]
15. The Impact of Chromatin Dynamics on Cas9-Mediated Genome Editing in Human Cells.
Daer RM; Cutts JP; Brafman DA; Haynes KA
ACS Synth Biol; 2017 Mar; 6(3):428-438. PubMed ID: 27783893
[TBL] [Abstract][Full Text] [Related]
16. [Applications of ZFN, TALEN and CRISPR/Cas9 techniques in disease modeling and gene therapy].
Zhao G; Pu J; Tang B
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2016 Dec; 33(6):857-862. PubMed ID: 27984622
[TBL] [Abstract][Full Text] [Related]
17. CRISPR: gene editing is just the beginning.
Ledford H
Nature; 2016 Mar; 531(7593):156-9. PubMed ID: 26961639
[No Abstract] [Full Text] [Related]
18. A beginner's guide to gene editing.
Harrison PT; Hart S
Exp Physiol; 2018 Apr; 103(4):439-448. PubMed ID: 29282799
[TBL] [Abstract][Full Text] [Related]
19. [The application of CRISPR/Cas9 genome editing technology in cancer research].
Wang DY; Ma N; Hui Y; Gao X
Yi Chuan; 2016 Jan; 38(1):1-8. PubMed ID: 26787518
[TBL] [Abstract][Full Text] [Related]
20. Cas9, Cpf1 and C2c1/2/3-What's next?
Nakade S; Yamamoto T; Sakuma T
Bioengineered; 2017 May; 8(3):265-273. PubMed ID: 28140746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
